This Is Not
a Pitch.

One billion people live with anxiety disorders. The global economic cost is $1 trillion every year. Every treatment ever developed — CBT, antidepressants, counselling, mindfulness, apps — was designed to manage symptoms indefinitely. Not one of them was designed to produce permanent recovery. Not one of them does.

In 1996, Charles Linden — himself a severe anxiety disorder sufferer — made a discovery that changed everything. He identified the precise neurological mechanism by which anxiety permanently deactivates and built a structured protocol, Threat Recalibration Therapy™ (TRT), to operationalise it. The result: 650,000 documented permanent recoveries across 42 countries. An NHS clinical trial returning an 84.5% full recovery rate — the largest single-methodology result on record. Thirty years of unbroken clinical evidence. No competitor anywhere in the world.

The Institute of Applied Psychophysiology is the Category of 1 business in a $1 trillion market where the structural problem — every existing treatment perpetuates the condition it claims to treat — has never been solved. CLI solved it. Thirty years ago.

CLI operates six commercial channels: digital recovery, KOTA/ANXAPP, premium residential retreats, elite sport, corporate and institutional, and schools. It serves every sector of society — individuals, employers, athletes, children, public services. The product is live. The evidence is documented. The infrastructure exists. Revenue projections reach $305M by Year 5 at 82%+ gross margin.

This document is not about whether CLI is a viable investment. It is about whether you understand the scale of what is on offer — and whether your organisation has the vision to claim a position in one of the most consequential commercial partnerships of this decade.

Every chronic disease category in history has had its defining structural moment — when management gave way to resolution. Diabetes had insulin. HIV had antiretrovirals. TB had streptomycin. In each case, the moment produced enormous commercial value and historic reputational consequence for those who backed it.

Anxiety disorder is the last major category still awaiting that moment. One billion people are affected. Every government, every health system, every employer is spending billions annually on management protocols that do not work. The science required to resolve this has existed since 1996. The platform required to deploy it at scale exists today. What has been absent is the commercial infrastructure to reach the global market.

That is what this investment creates.

Sources: WHO Global Health Estimates 2023; World Economic Forum; NICE CG113; CLI research archive 1996–2026.

CLI operates in a domain where commercial returns and public good are identical. The investors and organisations that back CLI do not simply generate exceptional financial returns — they become publicly identified as the people who funded the end of the global anxiety epidemic.

Consider what that means in practice.

• KOTA and ANXAPP reach millions of children and families. Parents who watch their children recover permanently from anxiety disorders — children who go from school refusal to full participation, from panic attacks to confidence — will know the names of the organisations that made that possible. No marketing campaign produces the brand loyalty that comes from giving a family their child back.
• The schools programme reaches every classroom. When CLI operates in 500, 1,000, 5,000 schools — and teachers, parents, and pupils know the organisations behind it — the reputational compound interest is extraordinary. CLI's investment partners are not hidden. They are credited.
• Elite sport creates global visibility. Rory Gibbs won Olympic Gold at Paris 2024 as a TRT graduate. Every athlete who recovers through the CLI sport programme represents a public endorsement of the system — and of the organisations that backed it.
• The NHS partnership positions investors as healthcare reformers. When CLI is commissioned by NHS ICBs and trusts — and it is heading there — the organisations behind that partnership are positioned alongside some of the most respected health reform stories of the decade.
• The 'before and after' story is the most powerful in commercial history. 650,000 people permanently recovered. Each one tells others. The network effects of a resolution-based product are categorically different from any management-based competitor. Investors share in that story.

The Mechanism

• Anxiety disorders are not psychological weaknesses or personality traits. They are the result of a malfunctioning amygdala/HPA axis — the brain's threat-prediction system — chronically calibrated to perceive danger in objectively safe situations.
• TRT issues a structured sequence of non-pharmacological inputs — behavioural, cognitive, and physiological — that command the threat-prediction system to return to its pre-anxiety baseline. The result is permanent resolution. The amygdala recalibrates. The disorder ends. There is no ongoing treatment requirement.
• CBT changes how patients think about anxiety. Medication suppresses the biochemical response. Mindfulness teaches observation of the state. TRT changes the neurological state itself. These are categorically different outcomes.
• Neurological recalibration is a biological mechanism — not a trend, not a framework. It cannot be disrupted. Evolution built it. Charles Linden discovered how to activate it deliberately.

The Moat — Why £200 Million and 30 Years Cannot Be Shortcut

• R&D Risk: Eliminated. No research phase. No development required. Four platforms are live, operational, and generating revenue. The asset exists and performs.
• Regulatory Risk: Eliminated. Psycho-educational delivery requires no clinical registration, no medical device approval, and no clinical oversight chain. Deploy at scale from day one.
• Platform Risk: Eliminated. An independent multi-platform ecosystem — digital, residential, professional, and diagnostic — each operationally self-sustaining.
• Competitive Risk: Eliminated. The 30-year dataset is the product. It cannot be replicated regardless of capital, timeline, or intent. The moat is biological time and 650,000 lived outcomes.
• Estimated cost to replicate from zero: £200M+ and 30 years. Any competitor beginning today cannot catch up in any commercially meaningful timeframe.

Sources: CLI research archive 1996–2026; NHS Hampshire Partnership Trust trial data 2019; NICE Evidence Appraisal Group review.

• NHS Clinical Trial (Hampshire Partnership Trust): 84.5% of participants met full recovery criteria at 6-month follow-up. GAD-7 reduction of 15.44 points. No CBT protocol, medication, or app has produced comparable outcomes at this scale.
• Tested and rated by NHS and Capita as the most effective anxiety intervention available — not the most promising, not the most innovative — the most effective.
• Rory Gibbs, Olympic Gold Medalist — Paris 2024: A TRT graduate. Performance anxiety, mechanistically identical to clinical anxiety disorder, responded to the same protocol. The world's most visible proof of concept.
• 30 years of continuous outcome data spanning every anxiety disorder classification: GAD, panic disorder, OCD, PTSD, social anxiety, agoraphobia, health anxiety, performance anxiety, eating disorders driven by anxiety, and child and adolescent anxiety.
• Trustpilot: 4.7/5 from thousands of independent, verified reviews — the highest rating of any anxiety recovery organisation on the platform.
• 42 countries served. 650,000 recoveries. No refund required on a permanent outcome.

Sources: CLI outcomes database 1996–2026; NHS Hampshire Partnership Trust 2019; Capita evaluation; Trustpilot (charleslinden.institute); Paris 2024 Olympic Games records.

CLI has spent 30 years building the most comprehensive anxiety recovery network on earth. This is not a website. It is a 15-domain global authority network, a residential estate across three countries, a practitioner accreditation system, a diagnostic app, and a 30-year organic search presence that no competitor can replicate with any amount of capital or time.

• 30 years of organic search authority for every high-intent anxiety keyword — 'anxiety recovery', 'Linden Method', 'panic attacks', 'OCD recovery', 'PTSD treatment'. This authority generates hundreds of thousands of monthly visits at near-zero acquisition cost.
• The 15-domain network creates a cross-linked authority web that no competitor can build by investment alone. Search authority of this depth requires the decades that have already been spent.
• Residential infrastructure: the Linden Centre (Oxfordshire), partner properties in Andalucía (Spain), and the UAE — operational, accredited, and programme-ready.
• Practitioner network: accredited TRT coaches operating globally through lindenanxietyrecovery.com — extending delivery reach without additional fixed cost.

CLI delivers TRT across six distinct commercial channels, each independently revenue-generating, each drawing from the same 30-year IP base and clinical evidence. No competitor operates at this breadth. No competitor could.

Channel 1 — Digital Recovery: The Linden Method

• thelindenmethod.direct: flagship home-learning TRT recovery programme. One-time enrolment at $1,500. Zero inventory. Zero fulfilment cost. 82%+ gross margin. 30,000 annual enrolments projected = $45M ARR from this product alone.
• The global digital delivery infrastructure is built and operating. Revenue scales with marketing investment, not with headcount, capacity, or physical property.
• Weekly live access to Charles Linden included with every enrolment. No other programme in the world offers this.

Channel 2 — KOTA / ANXAPP: The World's First Diagnostic Recovery App

• ANXAPP (anx-app.com, kota-anxapp.com) is the world's first app combining anxiety predisposition screening, clinical-grade diagnosis, and structured TRT recovery in one platform. No comparable product exists — every other mental health app offers coping tools.
• KOTA is the next-generation platform: enhanced diagnostic engine, practitioner portal, employer dashboard, population health analytics. The most scalable technology investment in the portfolio.
• The children and families market is where KOTA creates its most powerful impact — and its most powerful reputational consequence for investors. Millions of parents will know who funded this.
• Revenue: 250,000 subscribers at £4.99/month = $18M ARR. 500,000 = $36M ARR.

Channel 3 — Anxiety Recovery Retreats

• Premium 5-day intensive TRT residential programmes at the Linden Centre (Oxfordshire), Andalucía (Spain), and the UAE. Programme yield: £12,000–£25,000 per participant.
• The only residential retreat on earth offering permanent anxiety resolution with a 30-year evidence base. Every wellness retreat, every psychiatric facility, every private hospital is selling management. CLI is selling the end of the condition.
• Return rate: graduates return for annual renewal programmes. Recurring yield per guest.

Channel 4 — Elite Sport Programme

• CLI has worked with professional athletes across football, cricket, rugby, golf, tennis, athletics, rowing, darts, snooker, skiing, basketball, American football, and motorsport for over 30 years.
• Rory Gibbs — Olympic Gold Medalist, Paris 2024 — is a TRT graduate. The most powerful proof of concept available in elite sport.
• Commercial model: club and federation partnership fees + per-athlete programme fees. Target: Premier League clubs, international cricket boards, Olympic committees, World Rugby.
• Only 1 in 10 affected athletes ever seek help — stigma drives the rest into silence. CLI's digital delivery removes that barrier entirely.

Channel 5 — Corporate & Institutional

• The only corporate mental health programme that produces permanent resolution — not EAP signposting, not counselling sessions, not resilience apps. The disorder ends.
• Anxiety costs UK employers £56 billion per year (Deloitte, 2023). 1 in 6 workers experiences anxiety disorder; 91% of cases go undetected. CLI removes the condition — not the symptoms.
• Pricing from £119 per seat per year. CHF 1,200–2,400 per employee. CHF 60M–120M for a 50,000-person corporate deployment. CHF 1.2B–2.4B for an insurer group contract on 1 million lives.
• Target sectors: Financial Services, Legal, Technology, Healthcare, Armed Forces, NHS, Police, Construction, Public Sector. Every sector is documented in CLI's organisational programme. Every sector has a quantified ROI case.

Channel 6 — Schools & Education

• 1 in 2 children show clinically identifiable anxiety symptoms. 50% of adult anxiety disorders emerge before age 14. School phobia now affects 1.8 million UK pupils.
• The CLI Schools Programme is the only accredited anxiety recovery curriculum built on a permanent resolution framework — not awareness sessions, not coping workshops.
• 24,000 secondary schools in the UK. 130,000+ globally. At $67 per pupil × 5,000 pupils average = $335,000 per school per year at full deployment.
• This is where investors achieve their most visible reputational impact. When CLI operates in thousands of schools, and every parent of a recovered child knows the organisations that funded it, the reputational return is incalculable.

Sources: IOC Consensus Statement; BJSM; Deloitte 2023; MHFA England 2023; DfE mental health statistics 2024.

CLI's organisational programme addresses every sector of the global economy. What follows is a summary of the documented ROI case for each. The full sector analysis — covering Financial Services, Legal, Technology, Professional Services, Media, Construction, Retail, Healthcare, NHS, Armed Forces, Police, Fire, Local Government, and Prison Service, alongside Education (Schools, MATs, Universities, FE) — is available on request.

• In every sector, the per-seat cost of CLI is a rounding error against the documented cost of inaction.
• CLI's digital delivery model removes every barrier to scale — no physical infrastructure, no waiting lists, no referral chains, no clinical registration requirement.
• 42 countries currently served. The global deployment is not aspirational. It is already operating.

Sources: Deloitte Mental Health at Work 2023; NHS Workforce Plan; Law Society; Construction Industry Training Board; MOD Annual Report; DfE.

The global anxiety conditions treatment market is valued at €21 billion today, rising to €28B+ by 2030 (CAGR 10%). These figures represent only the diagnosed, treatment-seeking population. The total addressable market — including the corporate, educational, and public sector channels — is multiples larger.

These figures represent a single sector (individual treatment). Institutional deployment — corporate, schools, NHS, MOD, insurer groups — multiplies these numbers significantly.

• CHF 1,200–2,400 per employee for corporate deployment → CHF 60M–120M for a 50,000-person organisation.
• CHF 1.2B–2.4B for an insurer group contract on 1 million lives.
• 5% market share is not an ambitious projection for the only provider of permanent resolution in a market where every competitor offers management.

Sources: Grand View Research Mental Health Market 2024; CLI internal financial model (unaudited management projections).

Sources: CLI internal financial model. Revenue projections are unaudited management estimates and are not a guarantee of future performance.

• Independent IP valuation: £8–12M — assets without obsolescence.
• The IP portfolio is owned entirely by APGII Ltd. There are no joint IP arrangements, no academic institution licensing requirements, and no third-party dependencies on the core methodology.

CLI accommodates a range of partnership and investment structures. What CLI will not accommodate is a partner who does not understand the scale of what is on offer and who is not prepared to act decisively.

• CLI welcomes direct discussions with investors and strategic partners whose focus spans any or all six channels: digital health, children's technology, sports performance, premium wellness, EdTech, corporate health, public sector commissioning, and consumer subscription.
• A full financial model, IP schedule, clinical outcomes data pack, and corporate information memorandum are available under mutual NDA.
• Facility tours: the Linden Centre (Oxfordshire), active retreat properties in Spain and the UAE, and a full KOTA platform demonstration can be arranged.
• Charles Linden is available immediately for direct conversation — by video conference, or in person.